Monitor for any subsequent conversion to Schedule 13D (activist intent) or insider trading patterns. The 13.4% stake gives the group significant blocking power on certain shareholder votes, but the passive certification suggests no near-term control contest. Watch for any amendments or changes in beneficial ownership.
Price Chart
Executive Summary
Fidelion Diagnostics Pte. Ltd., together with affiliated entities (Molecule Bio LLC, Rainy Morning Technology (Hong Kong) Limited, and Ling Xiao), filed a Schedule 13G disclosing beneficial ownership of 392,329 shares of BioNexus Gene Lab Corp common stock, representing 13.4% of the 2,933,442 shares outstanding as of the company's June 30, 2026 Form 10-Q. The filing is passive (Rule 13d-1(c)) with no intent to influence control, and the stake is held directly by Fidelion Diagnostics, with shared voting and dispositive power among the reporting persons. This is a new 13G filing — no prior filing is referenced — and the 13.4% stake is substantial, signaling significant insider/affiliate conviction, but the passive nature limits immediate market impact.
Key Financial Metrics
Key Facts
- Fidelion Diagnostics Pte. Ltd. and affiliates disclose 392,329 shares (13.4% of outstanding) in BioNexus Gene Lab Corp.
- Stake based on 2,933,442 shares outstanding per the company's June 30, 2026 Form 10-Q.
- Filing is passive under Rule 13d-1(c) — no intent to change or influence control.
- Reporting persons include Fidelion Diagnostics (Singapore), Molecule Bio LLC (Wyoming), Rainy Morning Technology (Hong Kong), and Ling Xiao (Singapore).
- Shares held directly by Fidelion Diagnostics; other reporting persons share voting and dispositive power as controlling shareholders.
- No prior 13G or 13D filing referenced — this appears to be an initial disclosure of a 5%+ position.
Financial Impact
13.4% stake valued at approximately $[●] (no market price provided in filing; stake value not calculable from document alone)
Risk Factors
- Potential future conversion to Schedule 13D if intent changes, which could signal activist or control-seeking behavior.
- Concentrated ownership may lead to governance conflicts or reduced public float liquidity.
- No disclosure of acquisition price or date — timing and cost basis unknown.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001520138-26-000439 |
| Document: 0001520138-26-000439-index-headers.html | 0001520138-26-000439 |
| Document: 0001520138-26-000439-index.html | 0001520138-26-000439 |
| Document: 0001520138-26-000439.txt | 0001520138-26-000439 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13G | $1.19 | awaiting T+20 | — | $1.16 (−2.52%) |
Oct 7, 2026 19d ago | 8-K | $1.34 | awaiting T+20 | — | $1.16 (−13.43%) |
Jun 5, 2026 20w ago | 8-K | $2.20 $2.10 | ▼ −4.55% | ▼ −6.41% | $1.16 (−47.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers